Does RASBURICASE Cause Disseminated intravascular coagulation? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Disseminated intravascular coagulation have been filed in association with RASBURICASE (Elitek). This represents 1.4% of all adverse event reports for RASBURICASE.
12
Reports of Disseminated intravascular coagulation with RASBURICASE
1.4%
of all RASBURICASE reports
3
Deaths
8
Hospitalizations
How Dangerous Is Disseminated intravascular coagulation From RASBURICASE?
Of the 12 reports, 3 (25.0%) resulted in death, 8 (66.7%) required hospitalization, and 2 (16.7%) were considered life-threatening.
Is Disseminated intravascular coagulation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RASBURICASE. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does RASBURICASE Cause?
Tumour lysis syndrome (116)
Methaemoglobinaemia (92)
Off label use (90)
Product use in unapproved indication (76)
Bacterial infection (75)
Fungal infection (73)
Cellulitis (72)
Clostridium difficile colitis (72)
Lymphoid tissue hypoplasia (72)
Lymphopenia (72)
What Other Drugs Cause Disseminated intravascular coagulation?
PREDNISOLONE (362)
METHOTREXATE (347)
DEXAMETHASONE (323)
METHYLPREDNISOLONE (307)
NIVOLUMAB (305)
CYCLOPHOSPHAMIDE (286)
TACROLIMUS (278)
PREDNISONE (277)
VINCRISTINE (245)
OXALIPLATIN (231)
Which RASBURICASE Alternatives Have Lower Disseminated intravascular coagulation Risk?
RASBURICASE vs RAVULIZUMAB
RASBURICASE vs RAVULIZUMAB-CWVZ
RASBURICASE vs REBAMIPIDE
RASBURICASE vs REBETOL
RASBURICASE vs REBIF